During the initial 12 hours post-fibrinolysis, increased MMP-1 activity due to inadequate TIMP-1 inhibition may contribute to adverse outcomes, including more frequent heart failure symptoms observed in patients with a lysis-PCI interval of ≤9.6 hours. This evidence concerns the gene TIMP1 and heart failure.